Therapeutics News

As a doctor in a busy medical office complex, the management of glaucoma patients is a standard part of my practice. As these patients are typically on at least one, and often several, medications, compliance issues frequently arise.

With the availability of a multidose vial of cyclosporine ophthalmic emulsion 0.05%, eye doctors have a new option for tailoring appropriate dry eye therapy for their patients.

Okogen Inc. announced $10 million in Series A funding to advance the development of the company’s candidate for viral conjunctivitis treatment, OKG-0301.

Latanoprostene bunod 0.024% once daily showed greater efficacy in lowering diurnal IOP compared with timolol maleate 0.5% twice daily in a large cohort of patients with open-angle glaucoma or ocular hypertension.

NEW YORK – Clinicians should prescribe dry eye treatments based on their experience and comfort level, experts at the Ocular Surface Disease and Wellness Symposium, held during Vision Expo East, told attendees.

ATLANTA – Many cases of Acanthamoeba keratitis are misdiagnosed as herpes, according to Zaina Al-Mohtaseb, MD, in a presentation on anterior segment infections here at SECO.

A single, 12-minute vectored thermal pulsation procedure presents a favorable alternative to the long-term use of oral antibiotics for meibomian gland dysfunction, according to researchers.

Patients treated with lifitegrast ophthalmic solution 5.0% in the OPUS-3 study reported a low level of discomfort post-instillation, with rapid relief and consistent improvement of tolerance over time.

ATLANTA – “We may be moving out of the era of single-agent response to corneal ulcers,” Aaron Bronner, OD, said here in a presentation at SECO. “This treatment will fail more frequently because of resistance trends.”

ATLANTA – Data suggest that nearly 50% of culture results in eye care indicate a form of Staphylococcus aureus or Staphylococcus epidermidis that is resistant to fluoroquinolones, Rich Mangan, OD, said here at SECO. However, if you are already treating a patient with a fluoroquinolone and, “you’re seeing clinically that the ulcer is improving, you’re justified to keep with it.”